T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores

Neurology India

Volumn 52, Issue 3, 2004, Pages 332-337

  Atasoy, Huseyin Tugrul ^b   Nuyan, Oguz ^a   Tunc, Tugba ^b   Yorubulut, Mehmet ^c   Unal, Aysun E ^d   Inan, Levent E ^b  

^a Finike State Hospital   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

^c Radiology Department   (Turkey)

^d ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Dentate nucleus; Iron; Magnetic resonance imaging; Parkinson's disease; Substantia nigra

Indexed keywords

ANTIPARKINSON AGENT; IRON;

ADULT; AGED; ARTICLE; BASAL GANGLION; BIOACCUMULATION; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DENTATE NUCLEUS; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; PUTAMEN; RANK SUM TEST; RATING SCALE; SCORING SYSTEM; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION; WILCOXON SIGNED RANKS TEST;

AGED; BRAIN CHEMISTRY; FEMALE; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROSPECTIVE STUDIES; SUBSTANTIA NIGRA;

EID: 7244242355     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hirsch EC, Brandel JP. Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis. J Neurochem 1991;56:446-51.
2. Jellinger K, Kienzl E, Rumpalmair G, Riederer P, Stachelberger H, Ben Shachar D, et al. Iron-melanin complex in substantin nigra of parkinsonian brains: An x-ray microanalysis. J Neurochem 1992;59:1168-71.
3. Youdim MB, Ben Shachar D, Riederer P. The enigma of neuromelanin in Parkinson's disease substantia nigra. J Neural Transm 1994;43:113-22.
4. Fujol J, Junque C, Vendrell P, Grau JM. Biological significance of iron-related magnetic resonance imaging changes in the brain. Arch Neurol 1992;49:711-7.
5. Thomas LO, Boyko OB, Anthony DC, Burger PC. MR detection of brain iron. AJNR Am J Neuroradiol 1993;14:1043-8.
6. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurol 1993;43:697-700.
7. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-20.
8. Youdim MB, Ben Shachar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia migra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 1989;126:47-54.
9. Drayer BP. Magnetic resonance imaging and extrapyramidal movement disorders. Eur Neurol 1989;29:9-12.
10. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-75.
11. Griffiths PD, Dobson BR, Jones GR, Clarke DT. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999;122:667-73.
12. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
13. Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 1999;17:213-22.
14. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurol 1995;45:1138-43.
15. Mondino F, Filippi P, Magliola U, Duca S. Magnetic resonance relaxometry in Parkinson's disease. Neurol Sci 2002;23:S87-8.
16. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 1995;65:710-24.
17. Chen JC, Hardy PA, Kucharchzyk W, Clauberg M, Joshi JG, Vourlas A, et al. MR of human postmortem brain tissue: Correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol 1993;14:275-81.
18. Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990;55:16-20.
19. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurol 1999;53:1026-231.
20. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-82.
21. Duguid JR, Delapaz R, DeGroot J. Magnetic resonance imaging of the midbrain in Parkinson's disease. Ann Neurol 1986;20:744-7.
22. Huber SJ, Chakeres DW. Magnetic resonance imaging in Parkinson's disease. Arch Neurol 1990;47:735-7.
23. Pujol J, Junque C, Vendrell P, Grau JM, Capdevila A. Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. Arch Neurol 1992;49:1119-22.
24. Stern MB, Braffman BH, Skolnick BE, Hurtig HI, Grossman RI. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurol 1989;39:1524-6.
25. International Committee of Medical Journal Editors. Statements from the Vancouver Group. BMJ 1991;302:1194.
26. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32:8125-7.
27. Braffman BH, Grossman RI, Goldberg HI. MR imaging of Parkinson's disease with spin-echo and gradient-echo sequences. Am J Roentgenol 1989;152:159-65.
28. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002;64:1037-48.
29. Double KL, Ben Shachar D, Youdim MR, Zecca L, Riederer P, Gerlach M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol Teratol 2002;24:621-8.
30. Schenck JF. Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths. J Neurol Sci 1995;134:10-8.
31. Oikawa H, Ssaki M, Tamakawa Y, Ehara S, Tohyama K. The substantia nigra in Parkinson's disease: Proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. AJNR Am J Neuroradiol 2002;23:1747-56.
32. Behnke S, Berg D, Becker G. Does ultrasound disclose a vulnerability factor for Parkinson's disease? J Neurol 2003;250:124-7.
33. Hirsch E, Graybiel A, Agid Y. Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;345-8.
34. Muthane U, Yasha Tc, Shankar SK. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol 1998;43:283-7.
35. Connor JR, Snyder BS, Asato R. Quantitative analysis of isoferritins in select regions of aged, parkinsonian and Alzheimer diseased brain. Neurochemistry 1995;65:717-24.
36. Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 1997;151:83-7.
37. Antonini A, Vontobel P, Psylla M, Gunther I, Maguire PR, Missimer J, et al. Complementary positron emission totmographic studies of the striatal dopaminergie system in Parkinson's disease. Arch Neurol 1995;52:1183-90.
38. Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson's disease as reveald by MR imaging. AJNR Am J Neuroradiol 2000;21:697-701.
39. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:148-55.
40. Waldvogel D, van Gelderen P, Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol 1999;46:123-5.